Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02730169 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism
A Phase 2 study, sponsored by Mereo BioPharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 271
- Enrollment target
NCT02730169: Completed Phase 2 study, sponsored by Mereo BioPharma.
NCT02730169 is a Phase 2 study that has completed, run by Mereo BioPharma. The registered enrollment target is 271 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (104% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02730169, a Phase 2 study, has completed, sponsored by Mereo BioPharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 271 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism. All subjects will be treated for a maximum of 24 weeks. Some subjects who complete 24 weeks of treatment will be invited to participate in a 6-month blinded safety extension study (Protocol MBGS206). The study is planned to enroll 268 subjects.
Primary Outcome
Percentage of patients with normalised testosterone i.e. testosterone in the range 300-1000ng/dL after 24 weeks of study treatment. The primary objective was considered met, if greater than or equal to 75% of the participants in any arm normalised.
Interventions
- DRUG Placebo
- DRUG BGS649
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 271 participants |
| Start Date | 2016-05-12 |
| Est. Completion | 2018-05-19 |
| Phase | Phase 2 |
What the finished NCT02730169 record still lists
NCT02730169 is an interventional study that assigns participants to a tested intervention. The registered 271 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (104% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02730169 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02730169 about?
NCT02730169 is a clinical study titled "Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism". The purpose of this study is to evaluate the safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism. All subjects will be treated for a maximum of 24 weeks. Some subjects who complete 24 weeks of treatment will be invited to participate in a 6-month blinded safety ex...
What is the current status of trial NCT02730169?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 271 participants. The study started on 2016-05-12. Estimated completion is 2018-05-19.
What interventions are being tested in trial NCT02730169?
The interventions under investigation include: Placebo (DRUG), BGS649 (DRUG).
Who is sponsoring clinical trial NCT02730169?
This trial is sponsored by Mereo BioPharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02730169's enrollment target sits among peer trials
271 205th of 2000 higher than 1,796 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03609216 · 271 participants · Phase 2
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
- NCT02468024 · 272 participants · Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
- NCT05519449 · 272 participants · Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- NCT06035939 · 272 participants · NA
SMYLS Multi-site Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI